

**RESOLUTION OF THE BOARD OF SUPERVISORS OF THE
COUNTY OF SANTA BARBARA, STATE OF CALIFORNIA**

**IN THE MATTER OF AUTHORIZING
PARTIAL SETTLEMENT OF THE
LAWSUIT FILED ON BEHALF OF THE
COUNTY OF SANTA BARBARA AND
THE PEOPLE OF CALIFORNIA
AGAINST PRESCRIPTION OPIOID
DISTRIBUTORS AND
MANUFACTURERS, ACCEPTANCE OF
FUNDS THROUGH THE CALIFORNIA
STATE ALLOCATION AGREEMENT,
AND EXECUTION OF BACKSTOP
AGREEMENTS WITH OUTSIDE
COUNSEL**

RESOLUTION NO. 25-216

WHEREAS, on December 11, 2018, the Santa Barbara County Board of Supervisors (Board of Supervisors) approved and authorized the Office of County Counsel to initiate litigation against distributors and manufacturers of prescription opioids, to recover the County's damages from opioid drug misuse caused by the deceptive marketing and sale of prescription opioids, and to obtain other remedies to mitigate this issue going forward;

WHEREAS, on January 8, 2019, the Board of Supervisors approved and authorized the contingent-fee outside counsel agreement with the law firm of Keller Rohrback, L.L.P. to assist with this litigation;

WHEREAS, on February 15, 2019, the Office of County Counsel with the assistance of Keller Rohrback filed litigation on behalf of the County and in the name of the People of California in the United States District Court for the Central District of California, which was consolidated into the nationwide Multi-District Litigation in the United States District Court for the Northern District of Ohio (Case No. 1:17-MD-2804). Defendants in the lawsuit include Purdue Pharma, L.P.; Purdue Pharma, Inc.; The Purdue Frederick Company, Inc.; Endo Health Solutions Inc.; Endo Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Teva Pharmaceuticals Industries, Ltd.; Teva Pharmaceuticals USA, Inc.; Cephalon, Inc.; Allergan PLC f/k/a Actavis PLC; Allergan Finance, LLC f/k/a Actavis, Inc. f/k/a Watson Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Actavis LLC; Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.; Mallinckrodt plc; Mallinckrodt, LLC; SpecGX LLC; Cardinal Health, Inc.; McKesson Corporation; AmerisourceBergen Drug Corporation; Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.; Mylan Pharmaceuticals, Inc.; West-Ward Pharmaceutical Corp.; Hikma Pharmaceuticals PLC; Walgreens Boots Alliance Inc. a/k/a Walgreen Co; Thrifty Payless, Inc.; Rite Aid Corporation; Richard S. Sackler; Jonathan D. Sackler; Mortimer D.A. Sackler; Kathe A. Sackler; Ilene Sackler Lefcourt; Beverly Sackler; Theresa Sackler; David A. Sackler; Trust for the Benefit of Members of the Raymond Sackler Family; Rhodes Pharmaceuticals L.P.; Rhodes Technologies Inc.; Rhodes Pharmaceuticals Inc.; Rhodes Technologies; Walmart, Inc.; CVS Health Corporation; CVS Pharmacy Inc.; and CVS RX Services, Inc.; Does 1 through 100, inclusive (the "lawsuit");

WHEREAS, the lawsuit alleges, *inter alia*, that defendants created a public nuisance, and violated the California Unfair Competition and the False Advertising laws by distributing large volumes of opioids in Santa Barbara County despite knowledge of the growing epidemic caused by opioid misuse, and by failing to prevent and report suspicious opioid orders as required by State and Federal law;

WHEREAS, on December 14, 2021, the Board of Supervisors adopted a Resolution to partially settle the lawsuit with opioid manufacturers and distributors Amerisource Bergen Corporation, Cardinal Health, Inc., McKesson Corporation, and Janssen Pharmaceuticals, doing business as Johnson & Johnson;

WHEREAS, on April 4, 2023, the Board of Supervisors adopted a Resolution to partially settle the lawsuit with pharmacy chains CVS Health Corporation and CVS Pharmacy, Inc., Walgreens Co., and Walmart Inc., along with opioid manufacturers Allergan Finance LLC (f/k/a Actavis, Inc., f/k/a Watson Pharmaceuticals, Inc.) and Allergan Limited (f/k/a Allergan plc, f/k/a Actavis plc), and Teva Pharmaceutical Industries Ltd. Inclusive of Teva Pharmaceuticals USA, Inc., the Actavis Generic Entities, and Anda Inc.;

WHEREAS, on July 16, 2024, the Board of Supervisors adopted a Resolution to partially settle the lawsuit with supermarket pharmacy The Kroger Co (Kroger);

WHEREAS, in early 2025, secondary manufacturers Alvogen, Inc., Amneal Pharmaceuticals, Inc., Apotex Inc., Hikma Pharmaceuticals USA Inc., Indivior Inc., Mylan Pharmaceuticals Inc., Sun Pharmaceutical Industries, Inc., and Zydus Pharmaceuticals (USA), Inc. (collectively, “the G8” settlements), offered to settle the opioid lawsuits against it and the State of California thereafter accepted the offer to settle;

WHEREAS, the State of California is estimated to receive up to \$62.7 Million in abatement funds from the G8 parties with the County of Santa Barbara estimated to receive up to approximately \$700,000 over 10 years;

WHEREAS, in order for the County to receive these funds, it must elect to participate in the G8 Settlement through execution of a Subdivision Participation and Release Form and execute eight Proposed California State-Subdivision Agreements Regarding Distribution and Use of Settlement Funds by October 8, 2025;

WHEREAS, the G8 Settlement Agreement and Proposed California State-Subdivision Agreements Regarding Distribution and Use of Settlement Funds require that the settlement funds be used for approved opioid abatement activities. As a litigating subdivision, the County of Santa Barbara may also use a portion of the settlement funds received for in-house and outside counsel attorneys’ fees and costs through execution of “backstop agreements”; and

WHEREAS, upon execution of the Settlement Participation form, the County of Santa Barbara covenants not to bring, file, or claim, or to cause, assist or permit to be brought, filed, or claimed, or to otherwise seek to establish liability against the G8 parties and their “Released Entities” as that term is defined in the Settlement Agreement for each’s conduct complained of in the lawsuit.

NOW, THEREFORE, IT IS HEREBY ORDERED AND RESOLVED

The Board of Supervisors for the County of Santa Barbara approves and authorizes County Counsel or her designee to execute the following documents by October 8, 2025, which shall partially settle the action *County of Santa Barbara and the People of the State of California v. Purdue Pharma, et al.* (Case No. 1:17-MD-2804):

1. The Subdivision Participation and Release Form for the G8 Settlement, execution of which shall release all claims against the G8 parties and their "Released Entities" as that term is defined in the Settlement Agreements for each's conduct complained of in the lawsuit;
2. Eight Proposed California State-Subdivision Agreements Regarding Distribution and Use of Settlement Funds, one for each settling G8 party, which shall enable the County of Santa Barbara to receive and direct the use of the settlement funds for approved opioid abatement activities; and
3. The Backstop Agreement, which will allow the County to pay the contingency fees of Outside Counsel Keller Rohrback from recovered G8 Settlement funds in an amount not to exceed 15% of the County's recovery plus costs.

PASSED, APPROVED, AND ADOPTED by the Board of Supervisors of the County Santa Barbara, State of California, on this 23rd day of September, 2025 by the following vote:

AYES: Supervisors Lee, Capps, Nelson and Lavagnino

NAYS: None

ABSENT: Supervisor Hartmann

ABSTAIN: None

ATTEST:


MONA MIYASATO
COUNTY EXECUTIVE OFFICER
CLERK OF THE BOARD

COUNTY OF SANTA BARBARA


By: Sheila de la Guerra
Deputy Clerk

By: [Signature]
Laura Capps, Chair
Board of Supervisors

RECOMMENDED FOR APPROVAL
AND APPROVED AS TO FORM:
RACHEL VAN MULLEM
COUNTY COUNSEL

By: 
3FD3031A867243E...
Deputy County Counsel

APPROVED AS TO ACCOUNTING
FORM:
BETSY M. SCHAFFER, CPA
AUDITOR-CONTROLLER

By: 
02BA147EF6A84DE...
Deputy Auditor-Controller